Earlier this year, a group at Pfizer published a study challenging the research that became the cornerstone of Sirtris, a high-profile company that is developing compounds to treat or prevent the diseases of aging. This set off a chain of questions over the Boston-area start-up, which was bought in 2008 by GlaxoSmithKline for a hefty $270 million.
Sirtris has captured headlines for its efforts to combat aging-related maladies. The company is testing compounds called sirtuin activators, named for their reported ability to activate SIRT1, an enzyme thought to play a crucial role in aging.
The Pfizer study suggested that resveratrol, a compound found in red wine, and other molecules under development at Sirtris, don’t really activate this key enzyme and may not even have the life-extending benefits that have been reported by Sirtris founder David Sinclair and others. Previous research had raised similar questions. But until recently, the debate was limited largely to the academic arena.
A piece in Nature outlines the rather technical arguments over Sirtris’s sirtuin activators and what it might mean for the company and for anti-aging research more broadly. “The sirtuin stuff has just sort of been a runaway train,” Brian Kennedy, biologist at the University of Washington in Seattle, told Nature. Kennedy was lead author on one of the papers that proposed that resveratrol’s apparent effect on sirtuins was an experimental artifact. “We might have caused the train to wobble a little, but it kept barrelling down the tracks,” he said.
According to Nature, the Pfizer study
…presented evidence that the compounds were inhibiting a slew of other proteins – and some of the mice taking high doses of the drugs died. The paper concluded that the Sirtris compounds and resveratrol were pharmacological dead-ends owing to “their highly promiscuous profiles”.
… Some labs have been unable to consistently reproduce Sinclair’s life-extending results in model organisms such as fruitflies and nematodes, and debate has simmered over whether SIRT1 activation truly mimics caloric restriction.
However, the article says
… Most researchers seem to agree with Sirtris that the SIRT1-activating compounds do have beneficial effects in mice. Rafael de Cabo at the National Institute on Aging in Baltimore, Maryland, and a co-author on the 2006 Nature paper, says that he has safely tested one of the compounds, SRT1720, in more than 1,000 mice, some of which received the compound for two years. At least three other groups have published data showing that SRT1720 is beneficial and non-toxic in mice.
Sirtris and GSK have dismissed the controversy. Because the company aims to market drugs that slow or prevent the diseases of aging rather than extend longevity, sirtuin activators’ effects on lifespan may not matter.
Derek Lowe, who writes the pharma industry blog In The Pipeline, has closely followed the latest dust-up. He concludes that the controversy will only be settled with the outcome of ongoing clinical trials of Sirtuins compounds. But, he notes,
But we may not find out very quickly. GSK has (like many other companies) a tendency to be rather close-mouthed about the progress of some of its research. When I worked in the nuclear receptor field, we all were very interested in the fate of a particular Glaxo compound, the first selective PPAR-delta ligand to go into the clinic. The company had talked about some animal and preclinical data, but we knew that they were taking it into humans (after all, it was listed that way in their pipeline updates). But it stayed listed like that. . .and stayed…and stayed…until, as the months and years passed, it became obvious to even the most optimistic observer that the compound’s development was (at the very least) extremely complicated, and (more likely) had actually quietly ceased a good while before, albeit with no change in its public status.
This new data poisoning tool lets artists fight back against generative AI
The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models.
Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist
An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.
Data analytics reveal real business value
Sophisticated analytics tools mine insights from data, optimizing operational processes across the enterprise.
The Biggest Questions: What is death?
New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.